Bioscience

MedAvante launches service to boost reliability of Alzheimer’s disease trials

June 2, 2010

By Flinn Foundation

[Source: PR NewsWire] – MedAvante, Inc., the leader in centralized evaluation of central nervous system (CNS) disorders, announced today it was launching its CQC Continuous Quality Control Service for trials assessing Alzheimer’s Disease. Its CQC Services are already in use for trials of other central nervous system disorders including depression, anxiety and schizophrenia in the United States, Europe, Asia, Latin America and South Africa.

For more information: MedAvante Launches Service to Boost Reliability of Assessments to Reduce Risk of Failed Alzheimer’s Disease Trials